Sign in Subscribe

Valneva’s Lyme Disease Vaccine Candidate Clears Key EMA Hurdle

Valneva shares surge after EMA validates its Lyme disease vaccine candidate developed with Pfizer. Phase 3 trial showed over 70% efficacy.

Valneva’s Lyme Disease Vaccine Candidate Clears Key EMA Hurdle
"Blacklegged ticks are known carriers of the pathogenic bacteria that causes Lyme disease." Credit: Jim Gathany, CDC/PHIL/Corbis
Already have an account? Sign in.